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Transcranial alternating current stimulation (tACS) is a re-emergent neuromodulation 
technique that consists in the external application of oscillating electrical currents that 
induces changes in cortical excitability. We present the case of a 16-year-old female with 
pharmaco-resistant juvenile myoclonic epilepsy to 3 antiepileptic’s drugs characterized 
by 4 myoclonic and 20 absence seizures monthly. She received tACS at 1 mA at 3 Hz 
pulse train during 60  min over Fp1–Fp2 (10–20 EEG international system position) 
during 4 consecutive days using an Endeavor™ IOM Systems device® (Natus Medical 
Incorporated, Middleton, WI, USA). At the 1-month follow-up, she reported a 75% 
increase in seizures frequency (only myoclonic and tonic–clonic events) and developed 
a 24-h myoclonic status epilepticus that resolved with oral clonazepam and intravenous 
valproate. At the 2-month follow-up, the patient reported a 15-day seizure-free period.
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INtRoDUCtIoN
Transcranial alternating current stimulation (tACS) is a neuromodulation technique that consists in 
the external and non-invasive application of oscillating electrical current wave. It uses any wave form 
possible, such as sinusoidal or rectangular current shape waves (1). This stimulation technique aims 
to interfere with ongoing oscillations in the brain and induces changes in cortical excitability. tACS 
modulates cerebral rhythms applied at specific electroencephalographic frequencies (0.1–80 Hz) and 
in the “ripple” range (140 Hz) (1–4). Therefore, if tACS is effective for cortical neuromodulation, its 
effect appears to be generalized to all the brain, instead of localized to a single cortical area (5). It 
has been postulated that tACS cortical effects are dependent on the stimulus intensity and frequency 
(2, 6); frequencies of 1–5 Hz are excitatory similar to anodal transcranial direct current stimulation 
(tDCS) when 1 mA intensity is used, while those higher than 10 Hz and low intensity of 0.4 mA are 
inhibitory such as cathodal tDCS (6–8).
FIGURe 1 | Interictal sleep (N1 stage) eeG scalp recording with generalized paroxysm of poly-spikes followed by fragmented 1–1.5 Hz spike and 
slow-wave complexes (*) mixed with slow waves at 3–4 Hz with higher amplitude in the anterior quadrants. Filters: 0.03–70 Hz, notch: 60 Hz, sensitivity: 
7 μV/mm.
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Juvenile myoclonic epilepsy is a generalized epileptic syn-
drome, which is conceptualized as originating at some point 
within the cerebral cortex, and rapidly engaging, bilateral 
distributing networks (9). Even though they are considered to 
be benign, it is estimated that up to 10–20% are refractory to 
pharmacological treatment (10), justifying the search for alterna-
tive treatments (11).
Neuling et al. (12) report that tACS can regulate brain oscilla-
tions in a frequency-dependent manner, thus, a clinical use can be 
given to this neuromodulation technique. Nonetheless, evidence 
regarding safety parameters and long-lasting after effects with 
tACS are still lacking. The objective of this paper is to present a 
clinical case regarding a patient with pharmaco-resistant juvenile 
myoclonic epilepsy who received treatment with tACS and devel-
oped serious adverse effects. This clinical trial received approval 
from the Bioethics and Research Committees of the National 
Institute of Neurology and Neurosurgery in Mexico City.
patient Case
We present the case of a 16-year-old female student, right-
handed patient diagnosed with pharmaco-resistant juvenile 
myoclonic epilepsy from the National Institute of Neurology and 
Neurosurgery at Mexico City, Mexico. Her past medical history 
includes atopy and frequent upper-airway infections, and an 
amygdalectomy at the age of 3 years old. She has no other relevant 
perinatal, psychiatric, or familiar past medical history.
The patient presented her first seizure at age 12  years, 
describing this first episode as a generalized tonic–clonic 
seizure followed by myoclonic seizures. She was first seen in 
our institute 3 years after this initial event. During this 3-year 
interval, she was treated with valproate, topiramate, and lamo-
trigine, showing no improvement of her seizure frequency and 
developing pharmacoresistance to these antiepileptic drugs. 
Her seizure frequency was of 4 myoclonic seizures and 20 
absence seizures per month, and only in rare occasion’s tonic–
clonic seizures (once every 2–3 months). She denied any type 
of status epilepticus in the past. Her antiepileptic treatment at 
the moment of the intervention was levetiracetam (1 g/TID), 
carbamazepine (300 mg/BID), and pyracetam (800 mg/TID). 
The patient was informed about the tACS as a neuromodula-
tion technique and was asked to participate in this intervention 
since she had pharmaco-resistant juvenile myoclonic epilepsy. 
After she signed the consent form to participate in this inter-
vention, the patient was enrolled. The vital signs, neurological 
and psychiatric findings were normal. The psychological 
evaluation with the Barcelona Test (13) and Trail Making Test 
showed difficulties to store and recall visuospatial information, 
inability to complete cognitively complex tasks, fluctuations 
in sustaining attention, and difficulties in finding strategies, 
planning and performance, these features are related to the 
frontal lobe of the brain. Her brain 3-T magnetic resonance 
was normal, and the 1-h video-EEG showed interictal inter-
mittent generalized paroxysms of spike-low wave at 3  Hz, 
polispike-slow waves at 3–4 Hz, and generalized slow rhythmic 
waves at 4  Hz with higher amplitude in the anterior quad-
rants (Figure 1). She also had several typical electro-clinical 
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myoclonic and absence seizures during the video-recording. 
Basic medical laboratory studies (cell blood count, liver func-
tion test, blood electrolyte levels, glucose, and renal function 
test) were normal. Carbamazepine and pyracetam blood levels 
were in recommended therapeutic range.
Intervention
The stimulation site was determined to be the most active epi-
leptiform zone by EEG visual inspection. The EEG device was 
a Galileo (EBNeuro, Firenze, Italy) with golden cup electrode 
(Natus Medical Incorporated, Middleton, WI, USA) (Figure 1). 
The alternating current was applied over Fp1 and Fp2 (10–20 EEG 
international system) via a disposable stainless steel subdermal 
needle (Cardinal Health, Dublin, OH, USA) 12  mm in length 
and 0.4  mm in diameter using an Endeavor™ IOM Systems-® 
(Natus Medical Incorporated, Middleton, WI, USA) as tACS. The 
stimulus consisted in a pulse train with a frequency of 3 Hz, 1 mA 
at 60 min during four consecutive days.
During the 4-day intervention period, the patient had a seizure-
free lapse. At her 1-month follow-up, she reported an increase in 
seizure frequency characterized by two myoclonic seizures, four 
tonic–clonic seizures, and a myoclonic status epilepticus lasting 
24 h, making it necessary to be treated at the emergency room 
with oral clonazepam (2 mg) and intravenous sodium valproate 
(1200  mg). We calculated an increase in seizure frequency as 
75% since her basal frequency was of four myoclonic events per 
month during last 6 months. After the intervention, she presented 
a total of seven ictal events. We emphasize the fact that she had an 
increase in her generalized tonic–clonic seizures frequency and 
developed her first status epilepticus. No other cognitive deficits 
or neurological deficits were mentioned or found during medical 
evaluation.
At the 2-month follow-up, the patient stated that she had a 
15-day seizure-free period. After this medical consultation, we 
lost contact with the patient.
DIsCUssIoN
We present the case of a female teenager with pharmaco-resistant 
juvenile myoclonic epilepsy who received tACS and developed a 
worsening of her epileptic syndrome including a myoclonic status 
epilepticus.
Epilepsy treatment options based on neurostimulation such 
as chronic intermittent vagal nerve stimulation (VNS) and 
responsive neurostimulation system based on deep brain and 
cortical stimulation (Neuropace, Mountain View, CA, USA) are 
approved by the Food and Drug Administration for the treatment 
of pharmaco-resistant focal epilepsy (14, 15). However, other 
non-invasive experimental neuromodulation techniques such 
as transcranial magnetic stimulation, deep brain stimulation 
(DBS), external trigeminal nerve stimulation, and tDCS have 
gained international medical attention in recent years (16). The 
underlying principle of these techniques relies on the idea that 
extrinsic stimulation can reduce hyperexcitability or interfere 
with the discharges of epileptogenic networks (11).
Vagal nerve stimulation, responsive neurostimulation sys-
tem, DBS, and external trigeminal nerve stimulation devices 
work in different ways, but share a similarity in the fact that 
most of them uses frequencies above 10  Hz, thus causing 
an inhibitory effect (17). Nevertheless, none of these neuro-
modulation therapies have been approved in the treatment 
of pharmaco-resistant genetic generalized epilepsy, and there 
exists a limited experimental experience for the use of these 
techniques in the treatment of pharmaco-resistant genetic 
generalized epilepsy.
Transcranial alternating current stimulation is a non-invasive 
stimulation technique that modulates ongoing neural oscilla-
tion at specific frequencies using different current wave forms 
(18). The waveform of the stimulation changes cyclically over 
time, with either sinus pulses or square pulses that penetrate the 
skull through the electrodes placed over the surface of the scalp 
or are transmitted through the eye and optic nerve to the brain 
(19, 20). The effects of tACS at the neuronal level highly depend 
on the parameters used, i.e., current density, frequency range, 
electrode size, and the location of the stimulation electrode 
(21). Most of the applied stimulation frequencies are within 
the human EEG frequency range inducing local oscillatory 
activity in a stimulated brain area (22). In tACS, a frequency 
that matches the endogenous frequency could entrain network 
oscillations, and in our tACS protocol, we used 3 Hz similar to 
the frequency of the spike-slow waves of our patient (21). This 
effect is known as phase-locked waves (1). Previous alternating 
current stimulation (ACS) studies using several frequencies (1, 
10, 15, 20, 30, and 45 Hz) during 5–10 min showed that only 
ACS delivered at 20 Hz over left motor cortex in healthy subjects 
induced increased excitability compared to other experimental 
protocols (23). However, combined ACS frequencies in delta 
(1–3 Hz), theta (5 Hz), alpha (10 Hz), and beta (20 Hz) ranges 
over the motor cortex in healthy subjects showed increased 
cortical excitability after theta–beta frequency stimulation, in 
comparison to alpha–alpha stimulation, the synergic mecha-
nism is unknown (24). To the best of our knowledge, tACS has 
never previously been used in patients with genetic generalized 
epilepsy (21).
Ozen et  al. tested tACS in an animal model using sinusoid 
patterns at slow frequency (0.8–1.7  Hz), recorded intracranial 
cortical neuronal activity, and found that tACS entrained 20 and 
16% of neurons in the neocortical and hippocampal areas, respec-
tively. These phase-locked neurons were intensity dependent. 
The intensities that effectively phase locked the spikes induced 
intracellular polarization values of 2–3 mA, suggesting that the 
stimulation intensity affected the number of spiking neurons 
recruited (25).
Alternating current stimulation-induced after effects are 
assumed to arise from synaptic-level processes (26), this long-
lasting effect persists up to 1 h (8). In our patient, the adverse 
effects were reported at the first month of follow-up. Previous 
studies using tACS only reported minor side effects including 
light itching sensation under electrodes, tingling, a burning 
sensation, mild headache, nausea, and fatigue (27–30).
The adverse effects that are described in our patient by tACS 
could be explained due to the low stimulus frequency that was in 
an excitatory range, thus leading to an increase in the neural firing 
and synchrony which caused an increase in the seizures number 
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and severity (8). Temporary modifications of the synapse once 
exposed to a rapidly alternating electrical field, alters the associ-
ated biochemical mechanisms, such as accumulation of calcium 
in the presynaptic nerve terminals leading to short-term synaptic 
plasticity effects thus causing an increase in neurotransmitter 
release (31).
Future clinical trials using tACS in generalized epilepsy 
potentially need to use frequencies higher than 10  Hz to 
modulate functional connectivity between the stimulated area 
and more distant but anatomically and functionally connected 
regions (32). Also, choosing the stimulation intensity is also a 
key consideration during tACS studies (33). Safety issues and 
long-term effects do need to be taken into consideration, as seen 
with our patient, at the 2-month follow-up she had a 15-day 
seizure-free period.
The limitations of our case report are the inherent to this type 
of studies, including the limited generalization of our findings 
to other type of genetic generalized epilepsies, lack of control of 
other unknown potential triggers of status epilepticus, and use of 
specific parameters of tACS.
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